Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all…
COSTA MESA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- TadHealth, a leading provider of school-based mental health technology, has been…
COSTA MESA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- TadHealth, a leading provider of school-based mental health technology, has been…
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for…
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for…
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track…
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track…
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities…
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities…
ORANGE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at…